Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
901 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02665416 | Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors | completed | Phase 1 | 94 | Hoffmann-La RocheINDUSTRY | 7 | Apr 7, 2020 | clinicaltrials |
| NCT01507168 | A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma | completed | Phase 2 | 185 | Hoffmann-La RocheINDUSTRY | 13 | Apr 3, 2020 |
| clinicaltrials |
| NCT02141295 | A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer(McCAVE) | terminated | Phase 2 | 197 | Hoffmann-La RocheINDUSTRY | 7 | Mar 25, 2020 | clinicaltrials |
| NCT02673710 | A Study to Assess the Impact of Sarcopenia on the Outcomes of Colorectal Cancer Patients Treated With Chemotherapy Combined With Bevacizumab | completed | — | 200 | Hoffmann-La RocheINDUSTRY | 1 | Mar 25, 2020 | clinicaltrials |
| NCT02892318 | A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML) | completed | Phase 1 | 40 | Hoffmann-La RocheINDUSTRY | 1 | Mar 13, 2020 | clinicaltrials |
| NCT00069121 | A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer | completed | Phase 3 | 1,886 | Hoffmann-La RocheINDUSTRY | 29 | Mar 6, 2020 | clinicaltrials |
| NCT01959386 | A Study of Trastuzumab Subcutaneous in Participants With Human Epidermal Growth Factor Receptor-2 (HER2) Positive Early Breast Cancer(HerSCin) | completed | — | 1,006 | Hoffmann-La RocheINDUSTRY | 1 | Mar 3, 2020 | clinicaltrials |
| NCT02541604 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors | terminated | Phase 1 / Phase 2 | 87 | Hoffmann-La RocheINDUSTRY | 11 | Feb 25, 2020 | clinicaltrials |
| NCT02613208 | A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer(Argo) | completed | — | 111 | Hoffmann-La RocheINDUSTRY | 1 | Feb 17, 2020 | clinicaltrials |
| NCT03155009 | A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer(ATALK) | completed | Phase 2 | 44 | Hoffmann-La RocheINDUSTRY | 1 | Feb 10, 2020 | clinicaltrials |
| NCT02071225 | A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia | completed | Phase 2 | 72 | Hoffmann-La RocheINDUSTRY | 1 | Feb 7, 2020 | clinicaltrials |
| NCT03068351 | Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma | completed | Phase 1 | 24 | Hoffmann-La RocheINDUSTRY | 3 | Feb 7, 2020 | clinicaltrials |
| NCT02605915 | Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer | completed | Phase 1 | 98 | Hoffmann-La RocheINDUSTRY | 1 | Feb 5, 2020 | clinicaltrials |
| NCT02350673 | A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 70 | Hoffmann-La RocheINDUSTRY | 6 | Jan 18, 2020 | clinicaltrials |
| NCT01898585 | An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma | completed | Phase 4 | 60 | Hoffmann-La RocheINDUSTRY | 1 | Jan 7, 2020 | clinicaltrials |
| NCT02031458 | A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer(BIRCH) | completed | Phase 2 | 667 | Hoffmann-La RocheINDUSTRY | 19 | Jan 6, 2020 | clinicaltrials |
| NCT01484483 | An Observational Study to Register the Incidence of Breast Cancer and Current Clinical Care Patterns in Kenya | completed | — | 400 | Hoffmann-La RocheINDUSTRY | 1 | Dec 23, 2019 | clinicaltrials |
| NCT01984242 | A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma(IMmotion150) | completed | Phase 2 | 305 | Hoffmann-La RocheINDUSTRY | 9 | Dec 23, 2019 | clinicaltrials |
| NCT01667562 | A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer(ESSENCE) | completed | Phase 3 | 375 | Hoffmann-La RocheINDUSTRY | 1 | Dec 20, 2019 | clinicaltrials |
| NCT02008227 | A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy(OAK) | completed | Phase 3 | 1,225 | Hoffmann-La RocheINDUSTRY | 31 | Dec 20, 2019 | clinicaltrials |
| NCT01988896 | Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 153 | Hoffmann-La RocheINDUSTRY | 6 | Dec 17, 2019 | clinicaltrials |
| NCT02304393 | A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 140 | Hoffmann-La RocheINDUSTRY | 6 | Dec 13, 2019 | clinicaltrials |
| NCT02788279 | A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370) | completed | Phase 3 | 363 | Hoffmann-La RocheINDUSTRY | 11 | Dec 11, 2019 | clinicaltrials |
| NCT02445586 | Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer | completed | Phase 4 | 52 | Hoffmann-La RocheINDUSTRY | 1 | Oct 29, 2019 | clinicaltrials |
| NCT01905943 | A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia | completed | Phase 3 | 979 | Hoffmann-La RocheINDUSTRY | 31 | Oct 28, 2019 | clinicaltrials |
| NCT00643565 | A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma. | completed | Phase 2 | 154 | Hoffmann-La RocheINDUSTRY | 14 | Oct 22, 2019 | clinicaltrials |
| NCT02954471 | Study of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Participants With Early/Metastatic Breast Cancer in Saudi Arabia | completed | — | 351 | Hoffmann-La RocheINDUSTRY | 1 | Sep 20, 2019 | clinicaltrials |
| NCT01926886 | A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC) | completed | Phase 3 | 102 | Hoffmann-La RocheINDUSTRY | 2 | Sep 18, 2019 | clinicaltrials |
| NCT02402712 | Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer | completed | Phase 3 | 418 | Hoffmann-La RocheINDUSTRY | 12 | Sep 6, 2019 | clinicaltrials |
| NCT02453087 | A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 66 | Hoffmann-La RocheINDUSTRY | 1 | Aug 29, 2019 | clinicaltrials |
| NCT02768207 | A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma | completed | Phase 2 | 40 | Hoffmann-La RocheINDUSTRY | 2 | Aug 28, 2019 | clinicaltrials |
| NCT02999672 | A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors(KAMELEON) | completed | Phase 2 | 20 | Hoffmann-La RocheINDUSTRY | 4 | Aug 28, 2019 | clinicaltrials |
| NCT02040935 | A Study of SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC Participants(HOMERUS) | completed | Phase 3 | 128 | Hoffmann-La RocheINDUSTRY | 1 | Aug 22, 2019 | clinicaltrials |
| NCT01739218 | A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV Ovarian, Tubal, or Peritoneal Cancer, Initially Unresectable(ANTHALYA) | completed | Phase 2 | 99 | Hoffmann-La RocheINDUSTRY | 1 | Aug 13, 2019 | clinicaltrials |
| NCT02876224 | Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors | completed | Phase 1 | 51 | Hoffmann-La RocheINDUSTRY | 2 | Aug 13, 2019 | clinicaltrials |
| NCT02302807 | A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211] | completed | Phase 3 | 931 | Hoffmann-La RocheINDUSTRY | 29 | Aug 1, 2019 | clinicaltrials |
| NCT01271803 | A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma | completed | Phase 1 | 131 | Hoffmann-La RocheINDUSTRY | 2 | Jul 29, 2019 | clinicaltrials |
| NCT02393898 | BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older | completed | — | 76 | Hoffmann-La RocheINDUSTRY | 1 | Jul 24, 2019 | clinicaltrials |
| NCT01667419 | A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma(BRIM8) | completed | Phase 3 | 498 | Hoffmann-La RocheINDUSTRY | 29 | Jul 23, 2019 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials